Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
22
SBFM Quote, Financials, Valuation and Earnings
Last price:
$1.44
Seasonality move
:
86.56%
Day range:
$1.41 - $1.48
52-week range:
$1.17 - $3.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.14x
P/B ratio:
0.29x
Volume:
21.2K
Avg. volume:
459.7K
1-year change:
-55.73%
Market cap:
$7M
Revenue:
$34.9M
EPS (TTM):
-$1.86
Analysts' Opinion
-
Consensus RatingSunshine Biopharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Sunshine Biopharma, Inc. has an estimated upside of 319.58% from its current price of $1.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $1.43.
Fair Value
-
According to the consensus of 1 analyst, Sunshine Biopharma, Inc. has 319.58% upside to fair value with a price target of $6.00 per share.
SBFM vs. S&P 500
-
Over the past 5 trading days, Sunshine Biopharma, Inc. has underperformed the S&P 500 by -1.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sunshine Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sunshine Biopharma, Inc. has grown year-over-year revenues for 23 quarters straight. In the most recent quarter Sunshine Biopharma, Inc. reported revenues of $9.4M.
Earnings Growth
-
Sunshine Biopharma, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Sunshine Biopharma, Inc. reported earnings per share of -$0.19.
Enterprise value:
-1.4M
EV / Invested capital:
-0.06x
Price / LTM sales:
0.14x
EV / EBIT:
--
EV / Revenue:
-0.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$12M
Return On Assets:
-19.55%
Net Income Margin (TTM):
-16.06%
Return On Equity:
-24.74%
Return On Invested Capital:
-23.9%
Operating Margin:
-5.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $20.4M | $33M | $37.3M | $8.4M | $9.4M | |
| Gross Profit | $7.1M | $9.9M | $12M | $2.8M | $3M | |
| Operating Income | -$8.6M | -$4.6M | -$4.9M | -$1.1M | -$532K | |
| EBITDA | -$8.5M | -$4.4M | -$4.6M | -$1M | -$436.1K | |
| Diluted EPS | -$2,358.48 | -$155.59 | -$1.86 | -$0.95 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5M | $40.9M | $25.4M | $26M | $28M | |
| Total Assets | $2.5M | $40.9M | $27.7M | $30.1M | $31.5M | |
| Current Liabilities | $471.6K | $480.2K | $5.1M | $4.5M | $6.7M | |
| Total Liabilities | $3.7M | $480.2K | $5.7M | $5M | $7.3M | |
| Total Equity | -$1.2M | $40.4M | $22M | $25M | $24.2M | |
| Total Debt | $3.5M | -- | $555.7K | $440.3K | $636.7K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.3M | -$11.8M | -$7.1M | -$1.4M | -$727.8K | |
| Cash From Investing | -$15M | -$2.1M | -$1.3M | -$578.4K | -$118.3K | |
| Cash From Financing | $1.4M | $7.2M | $6.1M | $1.9M | $75.5K | |
| Free Cash Flow | -$8.7M | -$14M | -$8.4M | -$2M | -$761.9K | |
SBFM
Sector
Market Cap
$7M
$28.5M
Price % of 52-Week High
36.67%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-83.93%
-1.33%
1-Year Price Total Return
-55.73%
-20.32%
Beta (5-Year)
0.733
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.43
200-day SMA
Sell
Level
$1.61
Bollinger Bands (100)
Sell
Level
1.39 - 1.73
Chaikin Money Flow
Sell
Level
-89.3M
20-day SMA
Sell
Level
$1.52
Relative Strength Index (RSI14)
Sell
Level
39.40
ADX Line
Sell
Level
17.24
Williams %R
Neutral
Level
-62.7934
50-day SMA
Sell
Level
$1.65
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
132.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2186)
Buy
CA Score
(Annual)
Level (0.3523)
Sell
Beneish M-Score
(Annual)
Level (-0.4506)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.2494)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.
Stock Forecast FAQ
In the current month, SBFM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBFM average analyst price target in the past 3 months is $6.00.
-
Where Will Sunshine Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sunshine Biopharma, Inc. share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Sunshine Biopharma, Inc.?
Analysts are divided on their view about Sunshine Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sunshine Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Sunshine Biopharma, Inc.'s Price Target?
The price target for Sunshine Biopharma, Inc. over the next 1-year time period is forecast to be $6.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBFM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sunshine Biopharma, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SBFM?
You can purchase shares of Sunshine Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sunshine Biopharma, Inc. shares.
-
What Is The Sunshine Biopharma, Inc. Share Price Today?
Sunshine Biopharma, Inc. was last trading at $1.44 per share. This represents the most recent stock quote for Sunshine Biopharma, Inc.. Yesterday, Sunshine Biopharma, Inc. closed at $1.43 per share.
-
How To Buy Sunshine Biopharma, Inc. Stock Online?
In order to purchase Sunshine Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SBFM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SBFM
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
0.29x
1.83x
Price / LTM sales
0.14x
1.60x
Growth Metrics
SBFM
Sector
Revenue growth
11.64%
4.85%
Earnings growth
79.47%
11.11%
Revenue (5-year growth)
340.11%
6.45%
Earnings forecast
--
-$0.20
Profitability
SBFM
Sector
Profitability FY 2024
$10.4M
$3.6M
Return on invested capital
-23.9%
-30.98%
Return on assets
-19.55%
-27.62%
Return on equity
-24.74%
-36.69%
Earnings Date
Last Earnings Date
Dec
8
Next Earnings Date
Dec
8
Estimated Next Earnings Date
Mar
9
Balance Sheet
SBFM
Sector
Total cash
$9.3M
$27.2M
Short term investments
--
$25.7M
Total assets
$30.6M
$79.7M
Long term debt
$636.7K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
